Jove
Visualize
Contact Us

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

77.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Ascl1 Restrains Erk1/2 To Promote Survival Of A Subset Of Neuroendocrine Lung Cancers.
  1. Home
  3. Ascl1 Restrains Erk1/2 To Promote Survival Of A Subset Of Neuroendocrine Lung Cancers.

Related Experiment Video

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.0K

ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers.

Ana Martin-Vega1, Svetlana A Earnest1, Alexander Augustyn2

  • 1Department of Pharmacology, UT Southwestern Medical Center, Dallas, Texas.

Molecular Cancer Therapeutics
|September 19, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

The transcription factor ASCL1 drives neuroendocrine lung cancers. Targeting DUSP6, a phosphatase, shows promise for treating these cancers by increasing active ERK1/2 and reducing tumor growth.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.0K

Related Experiment Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • ASCL1 is a key oncogene in small cell lung cancer (SCLC) and neuroendocrine (NE) non-small cell lung cancer (NSCLC).
  • Targeting ASCL1 and its pathways is challenging.
  • ASCL1-expressing lung tumors show low ERK1/2 activity, unlike other NSCLCs.

Purpose of the Study:

  • To investigate the role of ERK1/2 pathway regulators in ASCL1-expressing lung cancers.
  • To explore DUSP6 as a potential therapeutic target in NE lung tumors.

Main Methods:

  • ERK1/2 inhibition in ASCL1-expressing lung tumor cells.
  • Chromatin immunoprecipitation sequencing (ChIP-seq) to identify ASCL1 targets.
  • Pharmacologic and genetic inhibition of DUSP6.
  • Analysis of ERK1/2 activity and cell proliferation/survival.

    • Main Results:

    • ERK1/2 inhibition downregulated SPRY4, SPRED1, DUSP6, and ETV5, all bound by ASCL1.
    • DUSP6 inhibition increased nuclear active ERK1/2.
    • DUSP6 inhibition reduced proliferation and survival in ASCL1-high NE lung tumors.
    • DUSP6 knockout cells developed resistance, suggesting bypass mechanisms.

    Conclusions:

    • ASCL1, DUSP6, and low phospho-ERK1/2 expression identify NE lung cancers.
    • DUSP6 is a potential therapeutic target for a subset of NE lung cancers.